Synonyms: loxicodegol (deleted INN) | NKTR-181 | NKTR181
Compound class:
Synthetic organic
Comment: Oxycodegol (NKTR-181; Nektar Therapeutics) is a μ-opioid receptor agonist analgesic [3]. It was designed to enter the brain slowly, so as to reduce CNS-mediated side effects and abuse potential.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Development progressed to completion of Phase 3 trials in chronic pain conditions [1-2], and to submission of a New Drug Application (NDA) to the FDA. However, upon unfavourable reviews by the FDA which concluded that the drug was unlikely to be approved, Nektar withdrew the NDA and terminated the development program. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02367820 | Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain | Phase 3 Interventional | Nektar Therapeutics |